NASDAQ: ASLN - ASLAN Pharmaceuticals Limited

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart ASLAN Pharmaceuticals Limited

Extended chart Simple chart
Financial Markets by TradingView

About ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co.

more details
, Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-05-04
ISIN US04522R1014
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aslanpharma.com
Цена ао 0.6
Change price per day: 0% (0.6)
Change price per week: 0% (0.6)
Change price per month: 0% (0.6)
Change price per 3 month: 0% (0.6)
Change price per half year: 0% (0.6)
Change price per year: -2.47% (0.6152)
Change price per 3 year: -29.88% (0.8557)
Change price per 5 year: -66.67% (1.8)
Change price per year to date: 0% (0.6)
All parameters

Underestimation

Title Value Grade
P/S 4.41 4
P/BV -3.98 0
P/E 0 0
EV/EBITDA -1.35 0
Total: 4.25

Efficiency

Title Value Grade
ROA, % -179.56 0
ROE, % 332.81 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.6183 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 4.45 1
Yield Ebitda, % 2792.47 10
Yield EPS, % 1015.89 10
Total: 8.2
More

Institutions Volume Share, %
BVF Inc. 1049999 13.82
UBS Group AG 625000 8.23
Citadel Advisors Llc 482963 6.36
Shay Capital LLC 400000 5.26
Sio Capital Management, LLC 254150 3.34
Renaissance Technologies, LLC 172801 2.27
Parkman Healthcare Partners LLC 110658 1.46
Landscape Capital Management LLC 83259 1.1
Millennium Management LLC 80362 1.06
Waterfront Wealth, Inc. 40941 0.54



Head Job title Payment Year of birth
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, CEO & Executive Director N/A 1973 (52 years)
Mr. Kiran Kumar Asarpota COO & Head of Finance N/A 1979 (46 years)
Mr. Ben Goodger General Counsel N/A 1963 (62 years)
Mr. Stephen Doyle Chief Business Officer N/A 1973 (52 years)
Dr. Alexandre Kaoukhov M.D. Chief Medical Officer N/A 1974 (51 year)
Charlie Hsu Investor Relations Director N/A
Chi-Chin Wang IR & Corporate Development Director N/A

Address: Singapore, Singapore, 3 Temasek Avenue - open in Google maps, open in Yandex maps
Website: https://aslanpharma.com